|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.480 USD | -8.07% |
|
-2.63% | -8.64% |
Company Valuation: Metagenomi Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Capitalization 1 | 135.1 | 60.83 | 55.57 | - | - |
| Change | - | -54.98% | -8.64% | - | - |
| Enterprise Value (EV) | 135.1 | 60.83 | 55.57 | 55.57 | 55.57 |
| Change | - | -54.98% | -8.64% | 0% | 0% |
| P/E ratio | -1.53x | -0.69x | -0.71x | -0.83x | -0.96x |
| PBR | - | - | - | - | - |
| PEG | 0x | - | 0.1x | 0.1x | 0.1x |
| Capitalization / Revenue | 2.58x | 2.41x | 1.96x | 2.2x | 3.91x |
| EV / Revenue | 0x | 0x | 1.96x | 2.2x | 3.91x |
| EV / EBITDA | -0x | - | -0.61x | -0.48x | - |
| EV / EBIT | -0x | -0x | -0.62x | -0.48x | -0.48x |
| EV / FCF | -0x | - | -0.69x | -0.54x | - |
| FCF Yield | -83% | - | -146% | -184% | - |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -2.36 | -2.36 | -2.09 | -1.781 | -1.545 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | 52.3 | 25.21 | 28.33 | 25.3 | 14.19 |
| EBITDA 1 | -83.49 | - | -91.5 | -115.5 | - |
| EBIT 1 | -88.9 | -96.01 | -90.2 | -114.8 | -115.6 |
| Net income 1 | -78.06 | -87.87 | -87.35 | -107.4 | -115.6 |
| Net Debt | - | - | - | - | - |
| Reference price 2 | 3.610 | 1.620 | 1.480 | 1.480 | 1.480 |
| Nbr of stocks (in thousands) | 37,424 | 37,547 | 37,547 | - | - |
| Announcement Date | 3/17/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71x | - | - | - | 55.57M | |
| 35.29x | 5.14x | 17.22x | 0.97% | 45.49B | |
| 54.35x | 4.68x | 31.54x | -.--% | 33.41B | |
| 56.43x | 11.55x | 32.31x | 0.34% | 31.32B | |
| 21.15x | 2.46x | 10.59x | -.--% | 29.29B | |
| -12.85x | 334.46x | -10.88x | -.--% | 19.5B | |
| 45.29x | 8.66x | 27.2x | -.--% | 14.77B | |
| 27.52x | 4.39x | 19.99x | -.--% | 13.36B | |
| 21.12x | 1.94x | 8.48x | 1.17% | 13.21B | |
| -18.31x | 14.28x | -19.9x | -.--% | 12.23B | |
| Average | 22.93x | 43.06x | 12.95x | 0.28% | 21.26B | |
| Weighted average by Cap. | 31.27x | 36.38x | 16.39x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- MGX Stock
- Valuation Metagenomi Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
